{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:59:46Z","timestamp":1789041586045,"version":"build-2803163510"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA107399\u201011A1"],"award-info":[{"award-number":["P50 CA107399\u201011A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HemaSphere"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Nivolumab is an anti\u2010PD\u20101 antibody that is effective in patients with relapsed\/refractory (RR) classic Hodgkin lymphoma (cHL). We previously showed PET\u2010adapted sequential nivolumab\u2009\u00b1\u2009ifosfamide, carboplatin, and etoposide (ICE) chemotherapy as the first salvage in RR cHL was a safe and effective bridge to autologous stem cell transplant (ASCT) (cohort A). We then tested a non\u2010PET\u2010adapted schema where all patients received nivolumab\u2009+\u2009ICE (cohort B). In this study, we present results from cohort B. Patients with high\u2010risk RR cHL after frontline treatment received 240\u2009mg nivolumab followed by 2\u20133 cycles of NICE (240\u2009mg nivolumab day 1, standard doses of ICE). High\u2010risk disease was defined as having one of the following: primary refractory cHL, relapse within 1 year of completing frontline therapy, B symptoms at relapse, extranodal disease at relapse, or frontline brentuximab vedotin use. PET\/CT was performed after nivolumab\u2009\u00d7\u20091 and NICE\u2009\u00d7\u20092. Responding patients (complete response [CR] or partial response) were intended to proceed to ASCT. The primary endpoint was CR rate per 2014 Lugano classification. A total of 35 patients were enrolled, all of whom were evaluable for safety and efficacy. Overall response rate and CR were 100% and 86%, respectively; 2\u2010year progression\u2010free survival (PFS) and overall survival (OS) were 88% and 100%, respectively. Thirty\u2010two patients proceeded to ASCT directly after NICE; 2\u2010year post\u2010ASCT PFS and OS were 94% and 100%, respectively. Immune\u2010related toxicities were all grades 1\u20132, and no patient discontinued treatment for toxicity. Nivolumab\/NICE is a highly effective salvage regimen and bridges patients effectively to ASCT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hem3.70126","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T20:05:39Z","timestamp":1746043539000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high\u2010risk relapsed\/refractory Hodgkin lymphoma"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-6955","authenticated-orcid":false,"given":"Matthew","family":"Mei","sequence":"first","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Computational and Quantitative Medicine City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Isufi","sequence":"additional","affiliation":[{"name":"Hematology and Bone Marrow Transplantation Yale University School of Medicine New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[{"name":"AstraZeneca New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni\u2010Chun","family":"Tsai","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Department of Computational and Quantitative Medicine City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro","family":"Armenian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics City of Hope Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Y.","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pathology City of Hope Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Baird","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swetha","family":"Thiruvengadam","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazeed","family":"Samara","sequence":"additional","affiliation":[{"name":"Department of Bone Marrow Transplant Southern California Permanente Medical Group Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flores","sequence":"additional","affiliation":[{"name":"Toni Stephenson Lymphoma Center, City of Hope Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lacolle","family":"Peters","sequence":"additional","affiliation":[{"name":"Toni Stephenson Lymphoma Center, City of Hope Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Rosen","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Herrera","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70013-6"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx791"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015423"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015423"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01056"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.7975"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282266"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26827"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18183"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003556"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-182318"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405888"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01315-1"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-861641"}],"container-title":["HemaSphere"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hem3.70126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hem3.70126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T16:12:25Z","timestamp":1771171945000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hem3.70126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1002\/hem3.70126"],"URL":"https:\/\/doi.org\/10.1002\/hem3.70126","archive":["Portico"],"relation":{},"ISSN":["2572-9241","2572-9241"],"issn-type":[{"value":"2572-9241","type":"print"},{"value":"2572-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"2024-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70126"}}